Close Menu
Home » HiSeq Sales Boost Illumina's Q3 Revenues, but Order Backlog Will Take Several Quarters to Fill

HiSeq Sales Boost Illumina's Q3 Revenues, but Order Backlog Will Take Several Quarters to Fill

Nov 02, 2010
Premium

This article was originally published Oct. 27.

By Julia Karow

Illumina said last week that demand for the HiSeq 2000 continued to exceed its expectations during the third quarter, prompting it to further increase production of the instrument.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Project to Discuss Race and Genetics in Class

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

Taking It All On

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

PLOS Papers on ASD-Related Syndrome, Twin Gut Microbiomes, Zika Virus Evolution

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

Unexpected Close

GenomeWeb reports that Veritas Genetics is suspending its US operations.

Dec
17
Featured Webinar

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

Sponsored by
Thermo Fisher Scientific

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

What's Popular?

In Clinical Sequencing

  1. Adaptive Biotechnologies, AbbVie Partner on MRD Testing in Multiple Myeloma Drug Trials

  2. ASH Study: Germline Testing Identifies Cancer Risk Mutations, VUS in Older AML Patients

  3. Gene Panel Finds Pathogenic Variants Missed by Standard Tests in 5 Percent of Familial Cancer Cases

  4. Illumina, ArcherDx Expand Partnership on NGS IVD Tests

  5. Childhood Kidney Cancer Arises From Altered Normal Tissue, Sequencing Study Finds

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.